In addition, 6-month treatment of type 2diabetic patients with hepatic steatosis with a GLP-1 receptor agonist promotednoticeable weight loss and significant reduction of intrahepatic lipid levels (8,9).However, the half-life of circulating GLP-1 is just 2 min in vivo,due to its rapid identification and cleavage by dipeptidyl peptidase-IV (DPP-IV)(10). Here, DPP4 is linked to fatty liver disease.